Hamilton BioVentures

Hamilton BioVentures, founded in 2000, is a California-based venture capital firm with $100 million under management. Specializing in early-stage biotech companies in the United States, Hamilton BioVentures invests in talented entrepreneurs developing innovative Life Science technology enterprises. Focusing on biopharmaceuticals and medical devices for major human diseases, their investments typically involve direct equity in early-stage companies on the West Coast.

Richard J. Crosby

Managing Director

Kerry Dance

Managing Director

Finlayson, Malcolm J. P.

Venture Partner

Donald W. Grimm

Director

Larry Knutson

VP of Finance

Elliot Parks

Director

12 past transactions

Splash is a privately held company that is developing novel cancer therapies with a goal to provide dramatic and durable responses in many solid tumors. Splash has developed a pipeline of novel agents that target CD44 with demonstrated anti-angiogenic and anti-metastatic activity as well as synergistic cytotoxicity with other chemotherapy agents. Splash is actively seeking Pharma partners to accelerate its novel clinical programs.

PhotoThera

Series C in 2006
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

PhotoThera

Series D in 2009
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared
Vycor Medical, Inc. is a medical device company committed to making neurological brain, spinal and other surgical procedures safer and more effective. Vycor's innovative medical instruments are designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery, and add tangible value to the professional medical community.

Troika Networks

Series B in 2005
Troika Networks, Inc. provides storage network data protection and management integrated solutions, hosting platforms, and enabling technologies. Its integrated solutions, application hosting platforms, and embedded technology provide a cost-effective approach for implementing disaster recovery, backup, and volume management functionality through original equipment manufacturers and resellers worldwide. The company was founded in 1998 and is based in Westlake Village, California.
AZUR is a privately held, venture funded company based in N. San Diego, CA. Its first product, the patient pending, eClips, allows users to 'clip out' real time information from any web site, internet or intranet, and view it from a wireless device. This product gives the consumer the ability to create a personalized web site and tracik key information on the web.

Splash Pharmaceuticals

Private Placement in 2018
Splash is a privately held company that is developing novel cancer therapies with a goal to provide dramatic and durable responses in many solid tumors. Splash has developed a pipeline of novel agents that target CD44 with demonstrated anti-angiogenic and anti-metastatic activity as well as synergistic cytotoxicity with other chemotherapy agents. Splash is actively seeking Pharma partners to accelerate its novel clinical programs.

Splash Pharmaceuticals

Series D in 2018
Splash is a privately held company that is developing novel cancer therapies with a goal to provide dramatic and durable responses in many solid tumors. Splash has developed a pipeline of novel agents that target CD44 with demonstrated anti-angiogenic and anti-metastatic activity as well as synergistic cytotoxicity with other chemotherapy agents. Splash is actively seeking Pharma partners to accelerate its novel clinical programs.

Ceregene

Series C in 2007
Ceregene is a private, San Diego-based biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Their clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor, which is about to enter Phase 2 studies for the treatment of Alzheimer's disease, and CERE-120, which recently completed a Phase 2 trial in Parkinson's disease and is currently being evaluated for future development. CERE-135 and CERE-140 are in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and ocular diseases, respectively.

Angstrom Pharmaceuticals, Inc.

Angstrom Pharmaceuticals, Inc. is a development stage pharmaceutical company that develops a new class of drugs targeting CD44 for the treatment of metastatic diseases and hematological malignancies. Its products range includes Å6, a CD44 binding peptide in clinical development for treating patients with ovarian cancer and chronic lymphocytic leukemia, as well as in preclinical development for the treatment of diabetic retinopathy and age-related macular degeneration. The company was founded in 1996 and is headquartered in Solana Beach, California.

PhotoThera

Series B in 2005
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

Transcept Pharmaceuticals

Series D in 2007
Transcept Pharmaceuticals, Inc. uses its proprietary delivery system to enhance the penetration of drugs, significantly speeding their onset of action. Transcept is developing rapid-acting versions of several major market pharmaceuticals. Hamilton co-invested in the company's first institutional round of funding alongside Montreaux Equity Partners, Peninsula Equity Partners and Vivo Ventures. Investors in subsequent financing rounds include these firms, and New Leaf Venture Partners, Interwest Partners and New Enterprise Associates.